In this article
FDA Grants Accelerated Approval to Zanubrutinib Plus Obinutuzumab for Relapsed or Refractory Follicular Lymphoma
March 2024: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) in combination with obinutuzumab has been granted accelerated approval by the Food and Drug Administration for the treatment of relapsed or refractory follicular lymphoma (FL) in patients who have had two or more lines of systemic therapy.
The effectiveness of the medication was assessed in Study BGB-3111-212 (ROSEWOOD; NCT03332017), which was a clinical trial including 217 adult patients with relapsed or refractory follicular lymphoma (FL) who had undergone at least 2 previous systemic therapies. The experiment was conducted at many centers and was open-label and randomized. The patients were randomly assigned in a ratio of 2:1 to receive either zanubrutinib at a dose of 160 mg orally twice daily until the disease progresses or there is unacceptable toxicity, in combination with obinutuzumab (ZO), or to receive obinutuzumab alone. The median number of previous treatment attempts was 3, with a range of 2 to 11.
The effectiveness of the treatment was assessed by an independent review committee, based on the overall response rate (ORR) and the duration of response (DOR). The overall response rate (ORR) was 69% (95% confidence interval [CI]: 61, 76) in the ZO arm and 46% (95% CI: 34, 58) in the obinutuzumab arm (two-sided p-value, 0.0012). After 19.0 months of observation, the median duration of response (DOR) was not determined in the ZO arm (95% CI: 25.3 months, NE), while it was 14.0 months (95% CI: 9.2, 25.1) for patients who received obinutuzumab monotherapy. In the ZO arm, the estimated rate of durable objective response (DOR) at 18 months was 69% with a 95% confidence interval (CI) of 58% to 78%.
In clinical studies of zanubrutinib, the most frequently seen negative effects (occurring in at least 30% of cases), which also include abnormal laboratory results, were reduced levels of neutrophils (51%) and platelets (41%), upper respiratory tract infections (38%), bleeding (32%), and musculoskeletal discomfort (31%). ZO caused serious adverse effects in 35% of patients with FL.
The suggested zanubrutinib dose is 160 mg administered orally twice day or 320 mg administered orally once daily unless there is disease progression or intolerable toxicity.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Susan Hau
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy. Hau's expertise lies in cancer cell biolo…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.